Compulsory Licensing Explained: How Governments Override Patents for Public Health

Imagine a life-saving drug exists, but its price is so high that millions cannot afford it. The patent holder refuses to lower the cost or license the technology to others. In this scenario, governments have a legal tool to step in. This tool is compulsory licensing, which is a government authorization allowing third parties to produce patented products without the consent of the patent owner, usually in exchange for reasonable compensation. It is not theft; it is a carefully regulated exception designed to balance private rights with public welfare.

This mechanism has been part of international law since the 1883 Paris Convention, but its modern shape comes from the 1994 TRIPS Agreement. While often discussed during health crises like the COVID-19 pandemic, compulsory licensing applies to various sectors, including agriculture and environmental technology. Understanding how it works reveals why it remains one of the most powerful yet underused tools in global health policy.

The Legal Foundation: TRIPS and Article 31

To understand compulsory licensing, you must look at the World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Specifically, Article 31 of TRIPS defines the specific conditions under which a member state can grant a compulsory license, ensuring adequate remuneration to the patent holder and predominantly domestic supply. This article sets the global standard. It ensures that while governments can override patents, they cannot do so arbitrarily. They must follow strict procedural rules.

Key requirements under Article 31 include:

• Adequate Remuneration: The patent holder must be paid fairly based on the economic value of the license.
• Domestic Supply: The production should primarily serve the local market, though exceptions exist for countries lacking manufacturing capacity.
• Individual Consideration: Each application must be judged on its own merits.
• Non-Exclusivity: The license is generally non-exclusive, meaning the original patent holder can still produce the product.

The Doha Declaration on TRIPS and Public Health (2001) clarified that these provisions are meant to protect public health. It affirmed that WTO members have the right to use compulsory licensing to access affordable medicines. This declaration removed much of the ambiguity that previously discouraged developing nations from using this tool.

How Different Countries Apply Compulsory Licensing

While TRIPS provides the framework, individual countries implement their own laws. These national frameworks vary significantly in ease of use and frequency of application. Let’s look at three distinct approaches: India, Brazil, and the United States.

India stands out as an aggressive user of this tool. Between 2005 and 2021, India issued 22 compulsory licenses, mostly for cancer medications. The landmark case involved Bayer’s Nexavar. When Bayer refused to lower the price, Natco Pharma applied for a compulsory license. The Indian Patent Office granted it, citing unaffordable prices and lack of working in the country. This single decision reduced the monthly cost of the drug from approximately $2,500 to $175.

Brazil uses compulsory licensing strategically to negotiate better terms. In 2007, Brazil issued a compulsory license for Merck’s efavirenz, an HIV medication. Rather than just producing it themselves, the threat of the license forced Merck to eventually agree to lower prices globally. This shows that the mere possibility of compulsory licensing can drive voluntary price reductions.

The United States takes a more restrictive approach. Its primary mechanism, Title 28 U.S.C. section 1498, allows the federal government to use patented inventions for public purposes. However, this is typically used for military or space applications, not consumer pharmaceuticals. The "march-in rights" under the Bayh-Dole Act allow the government to compel licensing of federally funded inventions if the patent holder fails to commercialize them effectively. Despite numerous petitions, the National Institutes of Health (NIH) has never granted a march-in right for drugs, arguing that the patent holders are already making the drugs available.

The Process: From Application to Production

Getting a compulsory license is not instantaneous. It involves a rigorous legal process. Here is what typically happens:

1. Negotiation Attempt: Under normal circumstances, the applicant must first try to obtain a voluntary license on reasonable commercial terms. This step proves that the patent holder is unwilling to cooperate.
2. Emergency Waiver: If there is a national emergency or extreme urgency (like a pandemic), the negotiation step can be skipped. This was seen in Spain’s 2020 Royal Decree-Law 6/2020 for coronavirus technologies.
3. Application Submission: The applicant submits a detailed request to the relevant authority (e.g., the Controller General of Patents in India or the Federal Circuit Court in the US).
4. Public Hearing: Authorities hold hearings where both the patent holder and the applicant present evidence regarding affordability, necessity, and technical capability.
5. Determination of Royalties: If granted, the court or agency determines the royalty rate. In India, this is often around 4-6% of net sales. In the US, courts use complex factors like the Georgia-Pacific factors to determine fair market value.
6. Issuance: The license is issued, specifying the scope, duration, and field of use.

This process can take months or even years. For example, Bayer’s challenge to India’s Nexavar license took eight years to fully resolve through the courts. This delay highlights a major limitation: compulsory licensing is slow, and patients suffering today may not benefit until long after the crisis peaks.

Impact on Innovation and Industry

Critics argue that compulsory licensing undermines innovation. Pharmaceutical companies spend billions on research and development (R&D), relying on patent exclusivity to recoup costs. A study published in the Journal of Health Economics (2018) suggested that active compulsory licensing frameworks could reduce R&D investment by 15-20% in affected markets. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) claims that each compulsory license announcement causes an average 8.2% drop in stock prices for affected firms.

However, proponents counter that the threat of compulsory licensing often leads to voluntary price cuts without actual implementation. Dr. Brook Baker notes that the mere presence of strong compulsory licensing laws helped secure voluntary price reductions for 90% of HIV medications in developing countries since 2000. Furthermore, many drugs sold under compulsory licenses are off-patent or have minimal remaining patent life, meaning the impact on future innovation is negligible.

The data supports a nuanced view. Compulsory licensing does not stop innovation globally; it redistributes access. Generic manufacturers like Teva Pharmaceutical Industries have reported billions in additional revenue from these markets, suggesting that a robust generic industry thrives alongside patent systems when balanced correctly.

Future Trends: Pandemics and Digital Health

The landscape of compulsory licensing is evolving. The COVID-19 pandemic sparked debates about waiving intellectual property rights entirely. In June 2022, the WTO agreed to a temporary waiver for COVID-19 vaccine patents. While significant, its practical impact was limited due to complex manufacturing supply chains and lack of technical transfer.

Looking ahead, several trends are emerging:

• Antimicrobial Resistance (AMR): As bacteria become resistant to existing drugs, new antibiotics are needed. The Boston Consulting Group predicts a 40% increase in compulsory licensing activity between 2023-2028, partly driven by AMR concerns.
• Climate Technology: Compulsory licensing may expand beyond health to include green technologies essential for climate adaptation, such as carbon capture methods.
• Streamlined Procedures: The EU’s 2023 Pharmaceutical Strategy proposes faster tracks for critical health technologies, requiring patent holders to respond within 30 days or face expedited licensing.

The ongoing negotiations for a WHO Pandemic Treaty include draft articles for automatic licensing during declared emergencies. If adopted, this would remove the need for case-by-case negotiations during crises, making the system more responsive.

Common Misconceptions About Compulsory Licensing

There is a lot of misinformation surrounding this topic. Let’s clear up three common myths.

Myth 1: Compulsory licensing means no payment to the inventor.
This is false. Article 31 explicitly requires "adequate remuneration." The patent holder always gets paid, though the amount is determined by the government or court, not the company itself.

Myth 2: It only happens in poor countries.
While developing nations use it more frequently for health reasons, wealthy nations have the same legal right. Germany, France, and the UK all have compulsory licensing laws. Germany has never issued one, but the legal framework exists. During WWII, the US issued thousands of compulsory licenses for German patents because diplomatic relations were severed.

Myth 3: It destroys the pharmaceutical industry.
The industry remains highly profitable. Most R&D profits come from high-income markets where compulsory licensing is rarely used. Developing markets represent a small fraction of total global sales. Therefore, overriding patents in low-income regions has minimal impact on overall corporate profitability.